Published April 18, 2022
- CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
- The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
- This review assesses colchicine (Myinfla), 0.5 mg extended-release oral tablet.
- Indication: For the reduction of atherothrombotic events in adult patients with existing coronary artery disease, in addition to standard therapies, including low-density lipoprotein cholesterol (LDL-C)–lowering and antithrombotic drug treatment.